Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant.

Rosko AE, Huang Y, Benson DM, Efebera YA, Hofmeister C, Jaglowski S, Devine S, Bhatt G, Wildes TM, Dyko A, Jones D, Naughton MJ, Byrd JC, Burd CE.

J Geriatr Oncol. 2018 Jul 5. pii: S1879-4068(18)30157-7. doi: 10.1016/j.jgo.2018.05.015. [Epub ahead of print]

PMID:
29983352
2.

Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways.

LaPak KM, Vroom DC, Garg AA, Guan X, Hays JL, Song JW, Burd CE.

Oncotarget. 2018 May 22;9(39):25386-25401. doi: 10.18632/oncotarget.25356. eCollection 2018 May 22.

3.

Spontaneous DNA damage to the nuclear genome promotes senescence, redox imbalance and aging.

Robinson AR, Yousefzadeh MJ, Rozgaja TA, Wang J, Li X, Tilstra JS, Feldman CH, Gregg SQ, Johnson CH, Skoda EM, Frantz MC, Bell-Temin H, Pope-Varsalona H, Gurkar AU, Nasto LA, Robinson RAS, Fuhrmann-Stroissnigg H, Czerwinska J, McGowan SJ, Cantu-Medellin N, Harris JB, Maniar S, Ross MA, Trussoni CE, LaRusso NF, Cifuentes-Pagano E, Pagano PJ, Tudek B, Vo NV, Rigatti LH, Opresko PL, Stolz DB, Watkins SC, Burd CE, Croix CMS, Siuzdak G, Yates NA, Robbins PD, Wang Y, Wipf P, Kelley EE, Niedernhofer LJ.

Redox Biol. 2018 Jul;17:259-273. doi: 10.1016/j.redox.2018.04.007. Epub 2018 Apr 13.

4.

Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.

Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, Mills GB, Sullivan RJ, Benchun M, Frederick DT, Boland G, Flaherty KT, Weeraratna AT, Herlyn M, Amaravadi R, Schuchter LM, Burd CE, Aplin AE, Xu X, Villanueva J.

EMBO Mol Med. 2018 May;10(5). pii: e8446. doi: 10.15252/emmm.201708446.

5.

Ultraviolet radiation accelerates NRas-mutant melanomagenesis: A cooperative effect blocked by sunscreen.

Hennessey RC, Holderbaum AM, Bonilla A, Delaney C, Gillahan JE, Tober KL, Oberyszyn TM, Zippin JH, Burd CE.

Pigment Cell Melanoma Res. 2017 Sep;30(5):477-487. doi: 10.1111/pcmr.12601. Epub 2017 Jul 4.

PMID:
28544727
6.

The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.

Farren MR, Hennessey RC, Shakya R, Elnaggar O, Young G, Kendra K, Landesman Y, Elloul S, Crochiere M, Klebanov B, Kashyap T, Burd CE, Lesinski GB.

Mol Cancer Ther. 2017 Mar;16(3):417-427. doi: 10.1158/1535-7163.MCT-16-0498. Epub 2017 Feb 1.

7.

Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.

Guan X, LaPak KM, Hennessey RC, Yu CY, Shakya R, Zhang J, Burd CE.

Mol Cancer Res. 2017 Mar;15(3):237-249. doi: 10.1158/1541-7786.MCR-16-0319. Epub 2016 Dec 30.

8.

Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms.

Burd CE, Gill MS, Niedernhofer LJ, Robbins PD, Austad SN, Barzilai N, Kirkland JL.

J Gerontol A Biol Sci Med Sci. 2016 Nov;71(11):1388-1394. Epub 2016 Aug 16.

9.

An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.

Souroullas GP, Jeck WR, Parker JS, Simon JM, Liu JY, Paulk J, Xiong J, Clark KS, Fedoriw Y, Qi J, Burd CE, Bradner JE, Sharpless NE.

Nat Med. 2016 Jun;22(6):632-40. doi: 10.1038/nm.4092. Epub 2016 May 2.

10.

The ability of endogenous Nras oncogenes to initiate leukemia is codon-dependent.

Kong G, Chang YI, You X, Ranheim EA, Zhou Y, Burd CE, Zhang J.

Leukemia. 2016 Sep;30(9):1935-8. doi: 10.1038/leu.2016.89. Epub 2016 Apr 25. No abstract available.

11.

Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.

Kong G, Chang YI, Damnernsawad A, You X, Du J, Ranheim EA, Lee W, Ryu MJ, Zhou Y, Xing Y, Chang Q, Burd CE, Zhang J.

Leukemia. 2016 Jul;30(7):1542-51. doi: 10.1038/leu.2016.40. Epub 2016 Feb 29.

12.

Ran Binding Protein 9 (RanBP9) is a novel mediator of cellular DNA damage response in lung cancer cells.

Palmieri D, Scarpa M, Tessari A, Uka R, Amari F, Lee C, Richmond T, Foray C, Sheetz T, Braddom A, Burd CE, Parvin JD, Ludwig T, Croce CM, Coppola V.

Oncotarget. 2016 Apr 5;7(14):18371-83. doi: 10.18632/oncotarget.7813.

13.

Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma.

Rosko A, Hofmeister C, Benson D, Efebera Y, Huang Y, Gillahan J, Byrd JC, Burd CE.

Bone Marrow Transplant. 2015 Oct;50(10):1379-81. doi: 10.1038/bmt.2015.143. Epub 2015 Jun 29. No abstract available.

14.

Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.

Burd CE, Liu W, Huynh MV, Waqas MA, Gillahan JE, Clark KS, Fu K, Martin BL, Jeck WR, Souroullas GP, Darr DB, Zedek DC, Miley MJ, Baguley BC, Campbell SL, Sharpless NE.

Cancer Discov. 2014 Dec;4(12):1418-29. doi: 10.1158/2159-8290.CD-14-0729. Epub 2014 Sep 24.

15.

Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma.

Jeck WR, Parker J, Carson CC, Shields JM, Sambade MJ, Peters EC, Burd CE, Thomas NE, Chiang DY, Liu W, Eberhard DA, Ollila D, Grilley-Olson J, Moschos S, Neil Hayes D, Sharpless NE.

Pigment Cell Melanoma Res. 2014 Jul;27(4):653-63. doi: 10.1111/pcmr.12238. Epub 2014 Apr 7.

16.

p16INK4a reporter mice reveal age-promoting effects of environmental toxicants.

Sorrentino JA, Krishnamurthy J, Tilley S, Alb JG Jr, Burd CE, Sharpless NE.

J Clin Invest. 2014 Jan;124(1):169-73. doi: 10.1172/JCI70960. Epub 2013 Dec 16.

17.

The molecular balancing act of p16(INK4a) in cancer and aging.

LaPak KM, Burd CE.

Mol Cancer Res. 2014 Feb;12(2):167-83. doi: 10.1158/1541-7786.MCR-13-0350. Epub 2013 Oct 17. Review.

18.

Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model.

Burd CE, Sorrentino JA, Clark KS, Darr DB, Krishnamurthy J, Deal AM, Bardeesy N, Castrillon DH, Beach DH, Sharpless NE.

Cell. 2013 Jan 17;152(1-2):340-51. doi: 10.1016/j.cell.2012.12.010.

19.

Circular RNAs are abundant, conserved, and associated with ALU repeats.

Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF, Sharpless NE.

RNA. 2013 Feb;19(2):141-57. doi: 10.1261/rna.035667.112. Epub 2012 Dec 18. Erratum in: RNA. 2013 Mar;19(3):426.

20.

Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk.

Burd CE, Jeck WR, Liu Y, Sanoff HK, Wang Z, Sharpless NE.

PLoS Genet. 2010 Dec 2;6(12):e1001233. doi: 10.1371/journal.pgen.1001233.

21.

What's so special about RB?

Burd CE, Sharpless NE.

Cancer Cell. 2010 Apr 13;17(4):313-4. doi: 10.1016/j.ccr.2010.03.010.

22.

Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas.

Chen W, Hilton IB, Staudt MR, Burd CE, Dittmer DP.

J Virol. 2010 Apr;84(8):3898-908. doi: 10.1128/JVI.01321-09. Epub 2010 Feb 3.

23.

Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging.

Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, Ibrahim JG, Thomas NE, Sharpless NE.

Aging Cell. 2009 Aug;8(4):439-48. doi: 10.1111/j.1474-9726.2009.00489.x. Epub 2009 May 22.

24.

INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis.

Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, Mohlke KL, Ibrahim JG, Thomas NE, Sharpless NE.

PLoS One. 2009;4(4):e5027. doi: 10.1371/journal.pone.0005027. Epub 2009 Apr 3.

Supplemental Content

Support Center